Q-omics provides the consensus-scored MRPL18 profile across patient tissues and cancer cell-line models. MRPL18 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MRPL18 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, MRPL18 protein abundance shows 21,548 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KICH, and LSCC as cancer lineages where MRPL18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL18 survival associations across molecular data types. MRPL18 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL18 RNA expression–survival associations across cancer types. High MRPL18 expression shows unfavorable associations in LIHC, KIRP, ESCA, BRCA and LUAD, but favorable associations in THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MRPL18 RNA expression.
This table summarizes MRPL18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL18 shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, LIHC, BLCA and LUSC. The KICH box plot shows higher MRPL18 RNA expression in normal versus tumor tissue (log2 FC = −1.457, t-test p < 0.001).
This table shows molecular features associated with MRPL18 in patient tissues and cancer cell lines. In patient samples, MRPL18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
